<DOC>
	<DOC>NCT02293564</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of gevokizumab in the treatment of active inflammatory, erosive osteoarthritis of the hand.</brief_summary>
	<brief_title>Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Diagnosis of hand osteoarthritis Joint tenderness and/or redness At least one erosion by Xray (as determined by the central reader) Contraceptive measures adequate to prevent pregnancy during the study History of inflammatory disease other than hand erosive osteoarthritis (EOA) including: secondary posttraumatic osteoarthritis (OA); rheumatoid arthritis; spondylarthropathies; erosion of the ulnar styloid process; psoriatic arthritis; skin psoriasis; erosions of the wrist; fibromyalgia History of gout, pseudogout, or hemochromatosis History of allergic or anaphylactic reactions to monoclonal antibodies History of recurrent or chronic systemic infections Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breastfeeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Erosive Osteoarthritis</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Osteoarthritis of the Hand</keyword>
</DOC>